HOME >> BIOLOGY >> NEWS
ChemGenex reports successful personalized dosing of Quinamed at ASCO

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 4, 2007). ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of data from its Quinamed (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors. The key outcomes from this study were (i) demonstration that dose level could be optimised according to patient genotype, (ii) the drug was well tolerated, with predictable and manageable side effects, and (iii) there was evidence of anticancer activity in several solid tumor types.

Dr. John Kuhn of the University of Texas Health Science Center in San Antonio, TX, along with the investigators at Sarah Cannon Cancer Center, TN and University of Louisville, KY discussed the data in an oral presentation at the American Association of Clinical Oncology (ASCO) 43rd Annual Meeting in Chicago, Illinois.

The clinical activity of amonafide against a variety of cancers has long been recognized, but development has been hampered by the unpredictable side effect profile for patients said Dr Kuhn. We are excited by the new opportunities that personalized dosing of Quinamed offers for a range of solid tumor patients who have developed resistance to existing therapies.

Highlights of the presentation included:

  • Confirmation that genotyping of patients prior to treatment allows for optimized personalized dosing and improved drug tolerance.
  • Patients with rapid and intermediate acetylator genotypes (who more rapidly metabolize the drug to the acetylated derivative associated with side effects) achieved a maximum tolerated dose (MTD) of 320 mg/m2 of Quinamed weekly, whilst patients with slow acetylator genotypes achieved an MTD of 400 mg/m2 of Quinamed weekly (three weeks on treatment followed by one week off treatment, repeated). Using these dosing regimens, 64% of
    '"/>


Contact: Joan Kureczka
jkureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
4-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biosite reports on presentation of preliminary data from sepsis program
4. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
5. Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity
6. Dinosaurs climate shifted too, reports show
7. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
8. Portion distortion may contribute to expanding waistlines, study reports
9. Study reports findings on lung cancer death rates in never smokers
10. Breast implants not associated with cancer risk, study reports
11. Paper reports discovery of virus implicated in genetics of prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... 2020 , ... BioFactura, Inc. today announced a $1 million ... & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD). ... efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for rapid ...
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/2/2020)... REDWOOD CITY, Calif. (PRWEB) , ... July 01, ... ... stage biotech company, presented its phase 1a findings of Neihulizumab, a biologic for ... annual conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... In most research using the ... pigment formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over ... been using the zebrafish model to investigate the causes of leukaemia and its ...
(Date:7/1/2020)... ... 29, 2020 , ... MedShift , a leading medical ... many obstacles created as a result of COVID-19. As a provider at the ... practices and medical manufacturers by expanding access to device offerings, technology services, and ...
(Date:6/28/2020)... ... June 25, 2020 , ... With ... a vaccine or drug treatment. In an effort to better understand the cellular ... the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... indoor environments, announced today that Derek Fournier has been appointed CEO and President. ... the Board, effective immediately. , “DeCurtis Corporation has been on an incredible ...
Breaking Biology Technology:
Cached News: